Management of INR 6.3 on Acenocoumarol
For a patient on acenocoumarol with an INR of 6.3 and no active bleeding, omit the next 1-2 doses of acenocoumarol and administer oral vitamin K1 1-2.5 mg, then resume anticoagulation at a lower dose when the INR falls into therapeutic range. 1
Risk Assessment First
Before implementing reversal, assess for:
- Active bleeding (any site - gastrointestinal, urinary, intracranial, retroperitoneal)
- High bleeding risk factors: age ≥65 years, history of stroke or GI bleeding, renal insufficiency, anemia, concomitant antiplatelet agents or NSAIDs 1
- Need for urgent surgery or invasive procedures
Management Algorithm for INR 5-9 Without Bleeding
Standard Approach (No High-Risk Features)
If the patient has no bleeding and no high-risk factors:
- Omit next 1-2 doses of acenocoumarol
- Resume at lower dose when INR approaches therapeutic range
- Recheck INR within 1-2 weeks 1
Recommended Approach (Safer Option)
Because INR 6.3 carries increased bleeding risk, vitamin K administration is preferred:
- Omit acenocoumarol
- Give oral vitamin K1 1-2.5 mg (oral route is predictably effective, convenient, and safe compared to IV or subcutaneous routes) 1
- This will lower INR to <5 within 24 hours in 95% of patients 1
- Resume acenocoumarol at a reduced dose when INR falls into therapeutic range
- Recheck INR in 24 hours to confirm downward trend 1
Route and Dose Considerations
Oral vitamin K1 is the treatment of choice for this scenario 1:
- Oral administration: Predictably effective, convenient, safe
- Avoid IV route: Risk of anaphylaxis, only use for life-threatening bleeding
- Avoid subcutaneous route: Unpredictable and delayed response 1
- Dose 1-2.5 mg is sufficient for INR 4-10 1
- Larger doses (5 mg) only needed when INR ≥10 1
Critical Pitfall to Avoid
Do NOT use high-dose vitamin K (10 mg) at this INR level - it will cause warfarin resistance lasting up to one week and may drop the INR below therapeutic range, exposing the patient to thromboembolic risk 1
If Active Bleeding Present
If the patient develops bleeding:
- Give oral vitamin K1 3-5 mg 1
- Expect INR fall within 24-48 hours
- Monitor closely and repeat vitamin K as necessary
- Consider hospital admission depending on bleeding severity
Special Consideration for Acenocoumarol
Acenocoumarol has a shorter half-life than warfarin or phenprocoumon. Recent evidence shows that after reversal with vitamin K and/or prothrombin complex concentrate, acenocoumarol users have lower risk of INR rebound compared to phenprocoumon users 2. This makes acenocoumarol somewhat easier to manage in supratherapeutic situations.
Follow-Up Strategy
- Recheck INR in 24 hours after vitamin K administration 1
- If INR remains elevated, give additional 1-2 mg vitamin K 1
- Once INR approaches therapeutic range, restart acenocoumarol at 20-30% lower dose than previous maintenance dose
- Monitor INR more frequently (every 3-7 days) until stable therapeutic range reestablished
Identify and Address Underlying Cause
Investigate why INR became supratherapeutic:
- Recent antibiotic use (especially fluoroquinolones, which can dramatically increase INR) 3
- Alcohol consumption 3
- Dietary changes (decreased vitamin K intake)
- New medications with drug interactions 4
- Acute illness affecting liver function or vitamin K absorption
- Medication non-adherence or accidental overdose